Research Paper Volume 3, Issue 4 pp 391—394
Pharmacological inhibition of NF-κB prolongs lifespan of Drosophila melanogaster
- 1 Institute of Biology, Komi Scientific Center, Ural Branch, Russian Academy of Sciences, Syktyvkar, Russia
Received: March 24, 2011 Accepted: March 27, 2011 Published: March 28, 2011
https://doi.org/10.18632/aging.100314How to Cite
Abstract
Aging is associated with NF-κB-dependent pro-inflammation. Here we demonstrated that inhibition of NF-κB with pyrrolidine dithiocarbamate increases the median lifespan (13-20%) and the age of 90% mortality (11-14%) in Drosophila melanogaster females and males, respectively.
Introduction
Aging is associated with diverse and widespread changes in gene expression in different animal species [1]. The NF-κB transcription factor is one of the major regulators of gene expression associated with mammalian aging [2-3]. NF-κB controls the expression of genes involved in innate immunity, inflammation and apoptosis [2,3]. Such age-dependent pathologies as tissue inflammation and atrophy are caused by over-activation of the NF-κB signaling with age [4-6]. We proposed that pharmacological inhibition of NF-κB will prevent age-related pathology and increase lifespan of Drosophila melanogaster. Three NF-κB transcription factors have been identified in Drosophila: Dorsal, Dif and Relish [7-9]. Like their vertebrate counterparts, these fly proteins contain an approximately 300-amino acid long, multifunctional and conserved Rel homology domain, which mediates dimerization, DNA binding, and interactions with IκB inhibitor proteins [7-9]. In this study we examined the effect of a specific NF-κB activity inhibitor, pyrrolidine dithiocarbamate (PDTC), on the lifespan of Drosophila melanogaster.
Results
In males pharmacological inhibition of NF-κB results in an increase of the median (by 20%) lifespan, as well as the age of 90 % mortality (by 14%), compared to males that did not receive PDTC treatment (Table, Figure 1). At the same time, the age-dependent mortality rate was not affected (χ2 = 0; df = 1) (Table, Figure 2). In females, pharmacological inhibition of the NF-κB transcription factor causes an increase in the median (by 13%) and maximum (by 11%) lifespan, as well as the age of 90 % mortality (by 6%), compared to females that did not receive PDTC treatment (Table, Figure 1). The inhibition of NF-κB factor increased the average and median lifespan (by 11-13%). The statistically significant decrease in the age-dependent mortality rate was detected in females as a result of NF-κB inhibitor effect (χ2 = 62.6; df = 1) (Table, Figure 2).
Figure 1. Effect of a NF-κB inhibitor (PDTC) on the survival functions. * p<0.001 Kolmogorov-Smirnov test.
Figure 2. Effect of a NF-κB inhibitor (PDTC) on the rate of the age-dependent mortality. * p<0.001 Maximum likelihood method.
Discussion
Recent studies suggest that the NF-κB transcription factor controls age-dependent changes in inflammation genes expression. Donato et al showed that an increase of NF-κB dependent genes in human endothelium with age is primarily linked to decreased IκB-mediated NF-κB inhibition [10]. Age-associated expression of NF-κB-dependent genes cause progression of athero-sclerosis in rat [11]. Furthermore, selective inhibition of NF-κB activity in blood vessel endothelial cells prevents atherosclerosis progression [12]. Genetic blockade of NF-κB in the skin of chronologically aged mice reverses the global gene expression program and tissue characteristics to those of young mice [13,14]. Decrease of NF-κB activity impedes progression of degenerative phenotype in mice with knocked out Sirt6 window sirtuin gene [15]. Kawahara et al suggested SIRT6 can prevent NF-κB-dependent gene overactivation via deacetylation of lysine 9 of the H3 histone (H3K9) on the promoters of NF-κB target genes, whereas over-activation of NF-κB promotes normal and accelerated aging [15]. However, the effect of NF-κB inhibition on the lifespan was not studied before. We have shown that pharmacological inhibition of NF-κB by pyrrolidine dithiocarbamate results in the considerable increase of longevity Drosophila melanogaster.
Methods
Drosophila melanogaster strains
The experimental orphan flies'genotype was y.
Pharmacological inhibition of NF-κB
Pyrrolidine dithiocarbamate (PDTC, Sigma) was used as a specific inhibitor of the NF-κB transcription factor [16]. The experimental flies where treated with yeast paste containing 20 mg/l PDTC throughout the lifetime. Control flies were fed with yeast paste without PDTC.
Lifespan analysis
Control and experimental flies were maintained at 25±0.5°C in a 12 h-12 h light/dark cycle on a sugar-yeast medium [17] covered with the yeast paste. To estimate the longevity 150-200 flies were collected during 24 h since the onset of eclosion (about 30 adult flies per 120 ml vial) for each experimental variant. Males and non-virgin females were kept separately. Flies were transferred to a fresh medium three times a week. Dead flies were counted daily. For each experimental variant 2-4 biological replicates were pooled. Survival functions were estimated using the Kaplan-Meier procedure and plotted as survival curves. Mean, median, minimum, and maximum lifespan, the age of 90% mortality were calculated. For aging rate estimates, the natural logarithm of age-dependent mortality rate ln(μ(x)) were used to determine the μ and R0 parameters of the Gompertz equation (μ(x) = R0eμx) and the mortality rate doubling time (MRDT) was calculated using the formula MRDT = ln2/μ [18]. The statistical analysis of survival data was conducted using nonparametric methods. Comparison of survival functions was done using the modified Kolmogorov-Smirnov test [19]. The statistical significance of differences between the median life spans for the experimental and control variants was determined using the Gehan-Breslow-Wilcoxon [20] and Mantel-Cox tests [21]. To test the statistical significance of differ-ences in maximum lifespan (age of 90% mortality), the Wang-Allison test was used [22]. According Wang-Allison test all animals from two compared variants were combined and the 90th percentile of the lifespan was calculated. Then each animal in each experimental variant was categorized into one of two groups: either lifespan above the 90th percentile or lifespan below the 90th percentile. The 2×2 contingency table was used to record data. The ordinary χ2-test was used for an independent test of two experimental variants. Therefore, a test of the equality of proportions above the 90th percentile across the variants was used as a test of the equality of the percentiles across the two variants [22]. The significance of differences in age-dependent mortality rate and initial mortality rate (parameters μ and R0 in the Gompertz equation) was evaluated using the maximum likelihood method [23]. Statistical analysis was carried out using Statistica version 6.1, StatSoft, Inc. and WinModest version 1.0.2 [23] software.
Table.
Longevity parameters of flies after pharmacological inhibition of the transcription factor NF-κB activity by PDTC
| Variant | Sex | M | 90 % | Min | Max | MRDT | α | R0 | n | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| −PDTC | Male | 42.8±0.3 | 44 | 56 | 3 | 72 | 7.3 | 0.095 | 0.0010 | 1156 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| +PDTC | 49.1±0.7 | 53* | 64* | 5 | 71 | 7.4 | 0.094 | 0.0005 | 381 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| −PDTC | Female | 58±0.4 | 61 | 72 | 9 | 82 | 6.7 | 0.104 | 0.00014 | 1187 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| +PDTC | 67.3±0.5 | 69* | 76* | 9 | 86 | 4.4 | 0.159* | 0.0001 | 322 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| p<0.001. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acknowledgments
This work was supported by a grant from the Presidium of the Russian Academy of Science № 09-P-4-1021 and grant from the Russian Foundation for Basic Research № 11-04-00956.
Conflicts of Interest
The authors of this manuscript have no conflict of interests to declare.
References
- 1. McCarroll SA, Murphy CT, Zou S, Pletcher SD, Chin CS, Jan YN, Kenyon C, Bargmann CI, Li H. Comparing genomic expression patterns across species identifies shared transcriptional profile in aging. Nat Genet. 2004; 36:197-204. [PubMed]
- 2. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. Linking JNK signaling to NF-κB: a key to survival. J Cell Sci. 2004; 117:5197-5208. [PubMed]
- 3. Chen LF and Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol. 2004; 5:392-401. [PubMed]
- 4. Kriete A and Mayo KL. Atypical pathways of NF-κB activation and aging. Exp Gerontol. 2009; 44:250-255. [PubMed]
- 5. Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011; 13:11-22. [PubMed]
- 6. Salminen A and Kaarniranta K. NF-κB signaling in the aging process. J Clin Immunol. 2009; 29:397-405. [PubMed]
- 7. Govind S. Control of development and immunity by Rel transcription factors in Drosophila. Oncogene. 1999; 18:6875-6887. [PubMed]
- 8. Gross I, Georgel P, Oertel-Buchheit P, Schnarr M, Reichhart JM. Dorsal-B, a splice variant of the Drosophila factor Dorsal, is a novel Rel/NF-κB transcriptional activator. Gene. 1999; 228:233-242. [PubMed]
- 9. Hoffmann JA. The immune response of Drosophila. Nature. 2003; 426:33-38. [PubMed]
- 10. Donato AJ, Black AD, Jablonski KL, Gano LB, Seals DR. Aging is associated with greater nuclear NFκB, reduced IκBμ, and increased expression of proinflammatory cytokines in vascular endothelial cells of healthy humans. Aging Cell. 2008; 7:805-812. [PubMed]
- 11. Wiggins JE, Patel SR, Shedden KA, Goyal M, Wharram BL, Martini S, Kretzler M, Wiggins RC. NFκB promotes inflammation, coagulation, and fibrosis in the aging glomerulus. J Am Soc Nephrol. 2010; 21:587-597. [PubMed]
- 12. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, Polykratis A, Kollias G, de Winther MP, Pasparakis M. Endothelial cell-specific NF-κB inhibition protects mice from atherosclerosis. Cell Metab. 2008; 8:372-383. [PubMed]
- 13. Adler AS, Kawahara TL, Segal E, Chang HY. Reversal of aging by NFκB blockade. Cell Cycle. 2008; 7:556-559. [PubMed]
- 14. Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY. Motif module map reveals enforcement of aging by continual NF-κB activity. Genes Dev. 2007; 21:3244-3257. [PubMed]
- 15. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, McCord RA, Ongaigui KC, Boxer LD, Chang HY, Chua KF. SIRT6 links histone H3 lysine 9 deacetylation to NF-κB-dependent gene expression and organismal life span. Cell. 2009; 136:62-74. [PubMed]
- 16. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med. 1992; 175:1181-1194. [PubMed]
- 17. Ashburner M. 1989; Drosophila: A laboratory manual. Cold Spring Harbor Laboratory Cold Spring Harbor, N.Y.
- 18. Finch CE. 1990; Longevity, senescence, and the genome. University of Chicago Press Chicago.
- 19. Fleming TR, O'Fallon JR, O'Brien PC, Harrington DP. Modified Kolmogorov-Smirnov test procedures with application to arbitrarily right-censored data. Biometrics. 1980; 36:607-625..
- 20. Breslow N. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika. 1970; 57:579-594..
- 21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50:163-170. [PubMed]
- 22. Wang C, Li Q, Redden DT, Weindruch R, Allison DB. Statistical methods for testing effects on ‘maximum lifespan’. Mech Ageing Dev. 2004; 125:629-632. [PubMed]
- 23. Pletcher SD. Model fitting and hypothesis testing for age-specific mortality data. J Evol Biol. 1999; 12:430-439..